Extended Data Fig. 3: Distribution of regional lymphocytic infiltration according to pathological stage.

All available patients’ data have been used in this figure except for the s.d. tests, where patients with a single tumor region were excluded. Patients without pathological staging information from the LATTICe-A cohort were also removed. a, b, c, top row: TRACERx and bottom row: LATTICe-A. Horizontal lines indicate the median value. a. Distribution of the s.d. of regional lymphocyte percentage for LUAD and LUSC patients in TRACERx (n = 69), and LUAD in LATTICe-A (n = 814). b. Distribution of the s.d. of regional lymphocyte percentage across pathological stages (n = 69 for TRACERx, 814 for LATTICe-A). c. Distribution of regional mean of lymphocyte percentage across stages (n = 79 for TRACERx, 827 for LATTICe-A). d. No significant difference among stages with respect to s.d. (n = 69 for TRACERx, 814 for LATTICe-A) or mean (n = 79 for TRACERx, 827 for LATTICe-A) of regional lymphocytic infiltration. Left panel, TRACERx and right panel, LATTICe-A. Correction for multiple testing was applied in d, for each cohort individually. A two-sided, non-parametric, unpaired, Wilcoxon signed-rank test was used; each dot represents a patient; the mean value is annotated with a large dot; the median value is represented by a thick horizontal line; minimum and maximum values are indicated by the extreme points; the first and third quantiles are represented by the box edges; and the violin shape shows the data distribution as a kernel density estimation.